DENTSPLY SIRONA Inc. (NASDAQ:XRAY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “DENTSPLY SIRONA's higher capital expenditure on product development and tough competition are expected to put margins under pressure. Unfavorable foreign exchange rate and integration are the major risks in the near term. The price performance of the stock has been unfavorable over the last three months. However robust performance by the company’s flagship dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic product platforms hold considerable promise over the long haul. The company recently announced the renewal of an existing distribution agreement with Henry Schein Canada, Inc. The agreement is a smart move by DENTSPLY SIRONA as the preexisting distribution agreement did not include the CEREC CAD/CAM restoration system and the Schick line of imaging sensors.”

Other analysts also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $68.00 target price on shares of DENTSPLY SIRONA in a report on Tuesday, October 3rd. Jefferies Group LLC lowered their target price on shares of DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating for the company in a report on Wednesday, August 23rd. Stifel Nicolaus reiterated a “buy” rating and issued a $66.00 target price (down previously from $70.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. BidaskClub upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Friday, June 30th. Finally, TheStreet downgraded shares of DENTSPLY SIRONA from a “b” rating to a “c+” rating in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $65.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.65. The company had revenue of $992.70 million during the quarter, compared to the consensus estimate of $1 billion. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.76 earnings per share.

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Upgrades DENTSPLY SIRONA Inc. (XRAY) to “Hold”” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/10/12/zacks-investment-research-upgrades-dentsply-sirona-inc-xray-to-hold.html.

A number of institutional investors and hedge funds have recently bought and sold shares of XRAY. Teachers Advisors LLC grew its position in DENTSPLY SIRONA by 5.6% during the first quarter. Teachers Advisors LLC now owns 341,126 shares of the medical instruments supplier’s stock valued at $21,300,000 after buying an additional 17,950 shares during the period. Royce & Associates LP grew its position in DENTSPLY SIRONA by 35.2% during the first quarter. Royce & Associates LP now owns 102,650 shares of the medical instruments supplier’s stock valued at $6,409,000 after buying an additional 26,750 shares during the period. Elk Creek Partners LLC grew its position in DENTSPLY SIRONA by 4.0% during the first quarter. Elk Creek Partners LLC now owns 5,587 shares of the medical instruments supplier’s stock valued at $349,000 after buying an additional 214 shares during the period. Legal & General Group Plc grew its position in DENTSPLY SIRONA by 2.9% during the first quarter. Legal & General Group Plc now owns 1,076,492 shares of the medical instruments supplier’s stock valued at $67,216,000 after buying an additional 30,544 shares during the period. Finally, EULAV Asset Management grew its position in DENTSPLY SIRONA by 6.3% during the first quarter. EULAV Asset Management now owns 94,500 shares of the medical instruments supplier’s stock valued at $5,901,000 after buying an additional 5,600 shares during the period. Institutional investors own 93.88% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.